Research · Sep 3, 2026
[PM] Philip Morris International Thesis 2026: Smoke-Free Conversion Inflection Tests Multi-Product Platform
Philip Morris International FY2025 revenue ~$40B (+7-9% YoY) with adj. operating margin ~37%. Smoke-free products reached ~42-43% of revenue (vs 29% FY2021) — strategic conversion thesis materializing. IQOS heated tobacco: 30M+ users, ~150B units, ~$11.5B revenue (global leader in heated tobacco). Zyn US: 770M cans, $3.2B revenue (+33%) — explosive growth post Swedish Match $16B Dec 2022 acquisition. Cigarettes ~$23B (~58% of revenue) declining ~2-3% volume but offset by price/mix. FY2026 thesis: IQOS toward 35M+ users (international expansion + eventual US relaunch post 2024 reacquisition from Altria); Zyn US continued +25-35% growth toward 1B+ cans annually; smoke-free mix toward 50%+ by FY2027; key risks: Zyn competitive intensity (BAT Velo + Altria on! + emerging brands), IQOS competition from BAT glo/Japan Tobacco Ploom in core markets, accelerating cigarette volume decline.